Multivariate analyses models for response and survival after induction chemotherapy in AML patients experiencing HMA failure
| Variable . | ORR, % . | OR . | 95% CI . | P . |
|---|---|---|---|---|
| Cytogenetic risk | 0.16-1.54 | .20 | ||
| Favorable/intermediate | 37.5 | 1 | ||
| Unfavorable | 21.1 | 0.42 | ||
| Anthracyclines | 0.57-10.37 | .23 | ||
| No | 18.8 | 1 | ||
| Yes | 37.2 | 2.43 |
| Variable . | ORR, % . | OR . | 95% CI . | P . |
|---|---|---|---|---|
| Cytogenetic risk | 0.16-1.54 | .20 | ||
| Favorable/intermediate | 37.5 | 1 | ||
| Unfavorable | 21.1 | 0.42 | ||
| Anthracyclines | 0.57-10.37 | .23 | ||
| No | 18.8 | 1 | ||
| Yes | 37.2 | 2.43 |
| Variable . | Median OS, mo . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| Therapy related | 0.66- 2.90 | .39 | ||
| No | 7.8 | 1 | ||
| Yes | 4.4 | 1.4 | ||
| Cytogenetic risk | 0.79-2.9 | .21 | ||
| Favorable/intermediate | 7.9 | 1 | ||
| Unfavorable | 4.5 | 1.5 | ||
| Prior induction | 0.74-3.14 | .25 | ||
| No | 7.8 | 1 | ||
| Yes | 3.7 | 1.5 | ||
| Disease status at HMA failure | 1.19-5.98 | .02 | ||
| Stable | 7.9 | 1 | ||
| Progressive | 4.0 | 2.66 | ||
| Use of anthracyclines | 0.17-0.82 | .01 | ||
| No | 3.7 | 1 | ||
| Yes | 8 | 0.37 |
| Variable . | Median OS, mo . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| Therapy related | 0.66- 2.90 | .39 | ||
| No | 7.8 | 1 | ||
| Yes | 4.4 | 1.4 | ||
| Cytogenetic risk | 0.79-2.9 | .21 | ||
| Favorable/intermediate | 7.9 | 1 | ||
| Unfavorable | 4.5 | 1.5 | ||
| Prior induction | 0.74-3.14 | .25 | ||
| No | 7.8 | 1 | ||
| Yes | 3.7 | 1.5 | ||
| Disease status at HMA failure | 1.19-5.98 | .02 | ||
| Stable | 7.9 | 1 | ||
| Progressive | 4.0 | 2.66 | ||
| Use of anthracyclines | 0.17-0.82 | .01 | ||
| No | 3.7 | 1 | ||
| Yes | 8 | 0.37 |
Logistic regression multivariate analysis model and Cox model for multivariate analysis of OS after induction therapy, including all covariates with a potential outcome on response in univariate analysis (P value in univariate <.15). Cytogenetic risk was evaluated per AML UK MRC classification.